Sonnet BioTherapeutics Holdings Inc Forecast, price target & analysts
Sonnet BioTherapeutics Holdings Inc Target price 2024 - Analyst rating & recommendation
Sonnet BioTherapeutics Holdings Inc Classifications & Recommendation:
Sonnet BioTherapeutics Holdings Inc Price Target
| Target Price | $14.67 |
| Price | $0.87 |
| Potential |
1,582.92%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Sonnet BioTherapeutics Holdings Inc 2025 .
The average Sonnet BioTherapeutics Holdings Inc target price is $14.67.
This is
1,582.92%
register free of charge
$30.00
3,342.34%
register free of charge
$7.00
703.21%
register free of charge
|
|
| A rating was issued by 3 analysts: 3 Analysts recommend Sonnet BioTherapeutics Holdings Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sonnet BioTherapeutics Holdings Inc stock has an average upside potential 2025 of
1,582.92%
register free of charge
|
Sales and Margin forecast 2024, 2025 & 2026
| Sep '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.15 | 0.10 |
| 57.14% | 33.33% | |
| EBITDA Margin | -12,286.67% | -15,000.00% |
| 50.36% | 22.08% | |
| Net Margin | -63,127.20% | -17,539.20% |
| 71.85% | 72.22% |
3 Analysts have issued a sales forecast Sonnet BioTherapeutics Holdings Inc 2024 . The average Sonnet BioTherapeutics Holdings Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Sonnet BioTherapeutics Holdings Inc 2024 . The average Sonnet BioTherapeutics Holdings Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2023 | $-18.4m | 35.56% |
|---|---|---|
| 2024 |
$-15.0m
18.61%
Unlock
|
|
EBITDA Margin
| 2023 | -12,286.67% | 50.36% |
|---|---|---|
| 2024 |
-15,000.00%
22.08%
Unlock
|
|
The average Sonnet BioTherapeutics Holdings Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2023 | -63,127.20% | 71.85% |
|---|---|---|
| 2024 |
-17,539.20%
72.22%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026
| Sep '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -18.14 | -3.36 |
| 87.94% | 81.48% | |
| P/E | negative | |
| EV/Sales | 11.30 |
Based on analysts' sales estimates for 2024, the Sonnet BioTherapeutics Holdings Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 18.83 | 137.15% |
|---|---|---|
| 2024 |
11.30
39.99%
Unlock
|
|
P/S ratio
| Current | 75.50 | 57.48% |
|---|---|---|
| 2024 |
45.30
40.00%
Unlock
|
|
Sonnet BioTherapeutics Holdings Inc...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
